all you really have to compare it to is AGN at a 70 million market cap before GLP and phase 1 studies in 2021, NYR is a more effective treatment with no need of combining it with thrombotics and a single therapy and not a dual therapy which is already proven to work
Current market cap is 22 million with 5 million in cash and 3-4 million in rebates coming after July 1st. Got a significant rerate to go as it was at 40 cents last time without it being proven and this current results exceeded modelling so previous highs will be tested short term
Nyrada Talks PreClinical Success with 180 Markets, page-91
Add NYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.2¢ |
Change
-0.001(1.59%) |
Mkt cap ! $11.12M | |||
| Open | High | Low | Value | Volume |
| 6.3¢ | 6.5¢ | 6.2¢ | $3.61K | 56.74K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 6.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.2¢ | 80 | 1 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.3¢ |
Change
-0.001 ( 1.56 %) |
||||
| Open | High | Low | Volume | ||
| 6.3¢ | 6.3¢ | 6.3¢ | 43043 | ||
| Last updated 15.09pm 24/05/2024 ? | |||||
| NYR (ASX) Chart |